633 related articles for article (PubMed ID: 11257041)
21. Susceptibility of methicillin-resistant Staphylococcus aureus clinical isolates to various antimicrobial agents. III. Novel, inducible resistance to macrolide-lincosamide-streptogramin B (MLS) antibiotics.
Inouye Y; Morifuji K; Masumi N; Sugiyama M; Takesue Y; Kodama T; Yokoyama T
Hiroshima J Med Sci; 1993 Sep; 42(3):101-7. PubMed ID: 8253604
[TBL] [Abstract][Full Text] [Related]
22. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
23. Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci.
Hamilton-Miller JM; Shah S
J Antimicrob Chemother; 2000 Dec; 46(6):941-9. PubMed ID: 11102413
[TBL] [Abstract][Full Text] [Related]
24. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus.
Low DE; Nadler HL
J Antimicrob Chemother; 1997 May; 39 Suppl A():53-8. PubMed ID: 9511063
[TBL] [Abstract][Full Text] [Related]
25. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.
Malbruny B; Canu A; Bozdogan B; Fantin B; Zarrouk V; Dutka-Malen S; Feger C; Leclercq R
Antimicrob Agents Chemother; 2002 Jul; 46(7):2200-7. PubMed ID: 12069975
[TBL] [Abstract][Full Text] [Related]
26. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
[TBL] [Abstract][Full Text] [Related]
27. Macrolide-lincosamide-streptogramin B resistance phenotypes in clinical staphylococcal isolates.
Cetin ES; Gunes H; Kaya S; Aridogan BC; Demirci M
Int J Antimicrob Agents; 2008 Apr; 31(4):364-8. PubMed ID: 18206352
[TBL] [Abstract][Full Text] [Related]
28. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
Bozdogan B; Leclercq R
Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
[TBL] [Abstract][Full Text] [Related]
29. [Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Pérez Salmerón J; Martínez García F; Roldán Conesa D; Lorente Salinas I; López Fornás F; Ruiz Gómez J; Gómez Gómez J; Segovia Hernández M; Valdés Chávarri M
Rev Esp Quimioter; 2006 Sep; 19(3):258-66. PubMed ID: 17099794
[TBL] [Abstract][Full Text] [Related]
30. Combining quinupristin/dalfopristin with other agents for resistant infections.
Brown J; Freeman BB
Ann Pharmacother; 2004 Apr; 38(4):677-85. PubMed ID: 14990776
[TBL] [Abstract][Full Text] [Related]
31. Subinhibitory quinupristin/dalfopristin attenuates virulence of Staphylococcus aureus.
Koszczol C; Bernardo K; Krönke M; Krut O
J Antimicrob Chemother; 2006 Sep; 58(3):564-74. PubMed ID: 16895938
[TBL] [Abstract][Full Text] [Related]
32. A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand.
Malbruny B; Werno AM; Anderson TP; Murdoch DR; Leclercq R
J Antimicrob Chemother; 2004 Dec; 54(6):1040-4. PubMed ID: 15537693
[TBL] [Abstract][Full Text] [Related]
33. Emergence of quinupristin/dalfopristin resistance among livestock-associated Staphylococcus aureus ST9 clinical isolates.
Yu F; Lu C; Liu Y; Sun H; Shang Y; Ding Y; Li D; Qin Z; Parsons C; Huang X; Li Y; Hu L; Wang L
Int J Antimicrob Agents; 2014 Nov; 44(5):416-9. PubMed ID: 25218154
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of quinupristin/dalfopristin in comparison with five antibiotics against worldwide clinical isolates of staphylococci.
Auckenthaler R; Courvalin P; Féger C; Roche G;
Clin Microbiol Infect; 2000 Nov; 6(11):608-12. PubMed ID: 11168064
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
36. Bactericidal activity of quinupristin-dalfopristin against Staphylococcus aureus: clindamycin susceptibility as a surrogate indicator.
Fuchs PC; Barry AL; Brown SD
Antimicrob Agents Chemother; 2000 Oct; 44(10):2880-2. PubMed ID: 10991879
[TBL] [Abstract][Full Text] [Related]
37. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination.
Matsumura S; Simor AE
Clin Infect Dis; 1998 Dec; 27(6):1554-6. PubMed ID: 9868693
[No Abstract] [Full Text] [Related]
38. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
Entenza JM; Drugeon H; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
[TBL] [Abstract][Full Text] [Related]
39. Occurrence of macrolide-lincosamide-streptogramin resistances among staphylococcal clinical isolates at a university medical center. Is false susceptibility to new macrolides and clindamycin a contemporary clinical and in vitro testing problem?
Sanchez ML; Flint KK; Jones RN
Diagn Microbiol Infect Dis; 1993; 16(3):205-13. PubMed ID: 8477574
[TBL] [Abstract][Full Text] [Related]
40. A high frequency of macrolide-lincosamide-streptogramin resistance determinants in Staphylococcus aureus isolated in South Korea.
Kim HB; Lee B; Jang HC; Kim SH; Kang CI; Choi YJ; Park SW; Kim BS; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2004; 10(3):248-54. PubMed ID: 15383170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
